免疫检查点抑制联合同步放化疗治疗不可切除Ⅲ期非小细胞肺癌的疗效与安全性:系统评价与Meta分析
该系统评价与Meta分析纳入7项试验共653例不可切除Ⅲ期非小细胞肺癌患者,评估同步放化疗联合免疫检查点抑制并继以免疫维持的疗效与安全性。单药免疫检查点抑制联合同步放化疗时任何原因肺炎发生率为33%(95%CI 28-39),CTCAE 3-5级为7%(95%CI 5-9);双免疫检查点抑制联合同步放化疗的试验中肺炎相关死亡达16%(95%CI 4-40)。作者认为在选定患者中单药免疫检查点抑制联合同步放化疗可管理,疗效与既往同步放化疗后免疫维持的数据似一致。
要点
- 单药免疫检查点抑制联合同步放化疗:任何原因肺炎33%(95%CI 28-39),CTCAE 3-5级肺炎7%(95%CI 5-9)。
- 一项双免疫检查点抑制(PD-1与CTLA4)联合同步放化疗试验中肺炎相关死亡为16%(95%CI 4-40)。
- 全部试验汇总客观缓解率69%(95%CI 63-76),中位无进展生存16.3个月、中位总生存39.5个月。
核心结论
- 在选定的Ⅲ期非小细胞肺癌患者中,同步放化疗联合单药免疫检查点抑制是可管理的,疗效结局似与既往同步放化疗后免疫维持的数据一致。
研究设计与样本
- 系统评价与Meta分析,纳入7项在Ⅲ期非小细胞肺癌患者中评估同步放化疗联合免疫检查点抑制并继以免疫检查点抑制维持的临床试验,共653例患者。
主要发现
- 单药免疫检查点抑制联合同步放化疗的试验中,任何原因肺炎发生率为33%(95%CI 28-39),CTCAE 3-5级肺炎为7%(95%CI 5-9)。
- 一项双免疫检查点抑制(PD-1与CTLA4)联合同步放化疗的试验中,肺炎相关死亡为16%(95%CI 4-40)。
- 全部试验汇总的客观缓解率为69%(95%CI 63-76)。
- 全部试验汇总的中位无进展生存为16.3个月(95%CI 14.0-20.5),中位总生存为39.5个月(95%CI 35.3-45.9)。
- 全部试验汇总的3年无进展生存率为36.8%(95%CI 32.7-41.4),3年总生存率为53.1%(95%CI 49.1-57.4);敏感性分析显示一项试验中同步放化疗前诱导化疗免疫治疗后联合免疫检查点抑制的3年无进展生存率为48.0%(95%CI 40.7-56.7)。
临床怎么用
- 在选定的Ⅲ期不可切除非小细胞肺癌患者中,同步放化疗联合单药免疫检查点抑制是可管理的,但双免疫检查点抑制联合同步放化疗与肺炎相关死亡增加相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with unresectable, stage III non-small cell lung cancer (NSCLC), durvalumab maintenance after concurrent chemoradiotherapy (cCRT) was shown to improve survival over placebo. As subgroup analyses indicated better outcomes with earlier start of durvalumab, several trials evaluated concomitant checkpoint inhibition (CPI) with cCRT. However, this may introduce an increased risk of treatment-related pulmonary toxicity. METHODS: We conducted a systematic review and meta-analysis of clinical trials of combined cCRT plus CPI followed by CPI maintenance in patients with stage III NSCLC. Endpoints included incidence of pneumonitis by any cause, objective response rate (ORR), progression-free (PFS), and overall survival (OS). RESULTS: A total of 7 trials comprising 653 patients were included. In trials of single-agent CPI with cCRT, pneumonitis occurred in 33 % of patients (95 % confidence interval [CI], 28-39) with 7 % (5-9) having CTCAE grade 3-5. In one trial, double CPI (PD-1 and CTLA4) plus cCRT was associated with excessive pneumonitis-related mortality of 16 % (4-40). Across all trials, ORR was 69 % (63-76). Median PFS and OS were 16.3 (95 % CI, 14.0-20.5) and 39.5 months (35.3-45.9), respectively. Three-year PFS and OS were 36.8 % (95 % CI, 32.7-41.4) and 53.1 % (49.1-57.4). Sensitivity analysis showed that induction chemoimmunotherapy prior cCRT plus CPI was associated with improved PFS of 48.0 % at 3 years (95 % CI, 40.7-56.7) in one trial. DISCUSSION: Addition of single-agent CPI to cCRT is manageable in selected patients with stage III NSCLC. Efficacy outcomes appear to be in line with previous data of cCRT followed by CPI maintenance.
引用
- Acker F, Reck M, Martin D, et al. Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis. Eur J Cancer. 2025. PMID: 39893747. doi:10.1016/j.ejca.2025.115266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。